CD22 and non-Hodgkin lymphoma: High differences were identified between all NHL subjects and normal controls regarding the percentage of EMAP II+CD4+, EMAP II+CD16+, EMAP II+CD20+, and EMAP II+CD22+ (P < 0.001).